CA2416538A1 - Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis - Google Patents
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis Download PDFInfo
- Publication number
- CA2416538A1 CA2416538A1 CA002416538A CA2416538A CA2416538A1 CA 2416538 A1 CA2416538 A1 CA 2416538A1 CA 002416538 A CA002416538 A CA 002416538A CA 2416538 A CA2416538 A CA 2416538A CA 2416538 A1 CA2416538 A1 CA 2416538A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- acid sequence
- amino acid
- sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (73)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21955600P | 2000-07-20 | 2000-07-20 | |
US60/219,556 | 2000-07-20 | ||
US22066400P | 2000-07-25 | 2000-07-25 | |
US22062400P | 2000-07-25 | 2000-07-25 | |
US60/220,664 | 2000-07-25 | ||
US60/220,624 | 2000-07-25 | ||
PCT/US2000/020710 WO2001009327A2 (en) | 1999-07-28 | 2000-07-28 | Method of preventing the injury or death of retinal cells and treating ocular diseases |
USPCT/US00/20710 | 2000-07-28 | ||
US22269500P | 2000-08-02 | 2000-08-02 | |
US60/222,695 | 2000-08-02 | ||
US09/643,657 US6642024B1 (en) | 1998-01-29 | 2000-08-17 | Guanylate-binding protein |
US09/643,657 | 2000-08-17 | ||
USPCT/US00/23522 | 2000-08-23 | ||
PCT/US2000/023522 WO2001016319A2 (en) | 1999-08-31 | 2000-08-23 | Compositions and methods for the treatment of immune related diseases |
USPCT/US00/23328 | 2000-08-24 | ||
PCT/US2000/023328 WO2001016318A2 (en) | 1999-09-01 | 2000-08-24 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US23097800P | 2000-09-07 | 2000-09-07 | |
US60/230,978 | 2000-09-07 | ||
US60/000,000 | 2000-09-15 | ||
US66461000A | 2000-09-18 | 2000-09-18 | |
US66535000A | 2000-09-18 | 2000-09-18 | |
US09/665,350 | 2000-09-18 | ||
US09/664,610 | 2000-09-18 | ||
US24292200P | 2000-10-24 | 2000-10-24 | |
US60/242,922 | 2000-10-24 | ||
US70923800A | 2000-11-08 | 2000-11-08 | |
US09/709,238 | 2000-11-08 | ||
USPCT/US00/30952 | 2000-11-08 | ||
PCT/US2000/030952 WO2001049715A2 (en) | 2000-01-06 | 2000-11-08 | Methods and compositions for inhibiting neoplastic cell growth |
PCT/US2000/030873 WO2001040465A2 (en) | 1999-11-30 | 2000-11-10 | Compositions and methods for the treatment of immune related diseases |
USPCT/US00/30873 | 2000-11-10 | ||
USPCT/US00/32678 | 2000-12-01 | ||
PCT/US2000/032678 WO2001040466A2 (en) | 1999-12-01 | 2000-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US00/34956 | 2000-12-20 | ||
PCT/US2000/034956 WO2001046420A2 (en) | 1999-12-23 | 2000-12-20 | Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
US09/747,259 US6569645B2 (en) | 1999-05-14 | 2000-12-20 | IL-17 homologous polypeptides and therapeutic uses thereof |
US09/747,259 | 2000-12-20 | ||
US09/767,609 US20020042367A1 (en) | 1997-11-25 | 2001-01-22 | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US09/767,609 | 2001-01-22 | ||
US79649801A | 2001-02-28 | 2001-02-28 | |
USPCT/US01/06520 | 2001-02-28 | ||
US09/796,498 | 2001-02-28 | ||
PCT/US2001/006520 WO2001068848A2 (en) | 2000-03-01 | 2001-02-28 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US01/06666 | 2001-03-01 | ||
PCT/US2001/006666 WO2001066740A2 (en) | 2000-03-03 | 2001-03-01 | Compositions and methods for the treatment of immune related diseases |
US80270601A | 2001-03-09 | 2001-03-09 | |
US09/802,706 | 2001-03-09 | ||
US80868901A | 2001-03-14 | 2001-03-14 | |
US09/808,689 | 2001-03-14 | ||
US09/816,744 US6579520B2 (en) | 1998-05-15 | 2001-03-22 | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US09/816,744 | 2001-03-22 | ||
US09/828,366 | 2001-04-05 | ||
US09/828,366 US20020010137A1 (en) | 1997-09-18 | 2001-04-05 | Methods and compositions for inhibiting neoplastic cell growth |
US09/854,280 | 2001-05-10 | ||
US09/854,208 US7217412B2 (en) | 1998-05-15 | 2001-05-10 | IL-17C related mammalian cytokine polypeptides |
US09/854,280 US7115398B2 (en) | 1998-05-15 | 2001-05-10 | IL-17 homologous polypeptides and therapeutic uses thereof |
US09/854,208 | 2001-05-10 | ||
US09/866,034 | 2001-05-25 | ||
USPCT/US01/17092 | 2001-05-25 | ||
PCT/US2001/017092 WO2001092331A2 (en) | 2000-05-30 | 2001-05-25 | Compositions and methods for the treatment of immune related diseases |
US09/866,034 US20030170864A1 (en) | 2000-05-30 | 2001-05-25 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US09/866,028 | 2001-05-25 | ||
US09/866,028 US6642360B2 (en) | 1997-12-03 | 2001-05-25 | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
PCT/US2001/017443 WO2002016611A2 (en) | 2000-08-24 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
USPCT/US01/17443 | 2001-05-30 | ||
US09/870,574 | 2001-05-30 | ||
US09/870,574 US6551799B2 (en) | 1999-12-07 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
PCT/US2001/017800 WO2001093983A1 (en) | 2000-06-02 | 2001-06-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US01/17800 | 2001-06-01 | ||
PCT/US2001/019692 WO2002000690A2 (en) | 2000-06-23 | 2001-06-20 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
USPCT/US01/19692 | 2001-06-20 | ||
USPCT/US01/00000 | 2001-06-28 | ||
PCT/US2001/021735 WO2002008284A2 (en) | 2000-07-20 | 2001-07-09 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2416538A1 true CA2416538A1 (en) | 2002-01-31 |
Family
ID=56290165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002416538A Abandoned CA2416538A1 (en) | 2000-07-20 | 2001-07-09 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1309685A2 (ja) |
JP (5) | JP2004516013A (ja) |
AU (1) | AU2001271973A1 (ja) |
CA (1) | CA2416538A1 (ja) |
WO (1) | WO2002008284A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000690A2 (en) * | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
JP4357738B2 (ja) | 1997-09-12 | 2009-11-04 | アポテック エール エ デ− エス.アー. | システインリッチなレセプターであるtrain |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
DK1076703T4 (da) | 1998-05-15 | 2011-03-28 | Genentech Inc | Terapeutiske anvendelser af IL-17-homologe polypeptider |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US20030190669A1 (en) | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
EP1623991A3 (en) * | 1999-09-01 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP1897947B1 (en) * | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
US20030158382A1 (en) * | 2000-04-21 | 2003-08-21 | Nobutaka Wakamiya | Novel collectins |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2275549A1 (en) * | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2075253A1 (en) * | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis |
US7265210B2 (en) | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
US6630325B1 (en) * | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
AU2002230778A1 (en) | 2000-11-03 | 2002-05-15 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
AU2002217838A1 (en) | 2000-11-14 | 2002-05-27 | Bristol-Myers Squibb Company | A human serpin secreted from lymphoid cells LSI-01 |
US20030119112A1 (en) | 2001-06-20 | 2003-06-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
AU2003215761A1 (en) * | 2002-03-22 | 2003-10-08 | Bioxell S.P.A. | A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
JPWO2003083114A1 (ja) * | 2002-03-28 | 2005-08-04 | アステラス製薬株式会社 | アンジオポエチン関連増殖因子 |
CA2481507A1 (en) * | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004022087A1 (ja) * | 2002-09-04 | 2004-03-18 | Takeda Pharmaceutical Company Limited | 疾患関連遺伝子の用途 |
JP2006512903A (ja) * | 2002-09-11 | 2006-04-20 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための新規組成物と方法 |
EP2500438A3 (en) * | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
US20100031378A1 (en) | 2008-08-04 | 2010-02-04 | Edwards Joel A | Novel gene disruptions, compositions and methods relating thereto |
JP5599136B2 (ja) | 2004-04-14 | 2014-10-01 | ジェネンテック, インコーポレイテッド | 血管の発達を調節するための、egfl7アンタゴニストを含む組成物 |
CA2572239C (en) | 2004-06-24 | 2019-07-09 | Mayo Foundation For Medical Education And Research | B7-h5, a costimulatory polypeptide |
US7410772B2 (en) | 2004-07-02 | 2008-08-12 | Genentech, Inc. | Compositions and methods for treatment of non-Hodgkin's lymphoma |
CA2576193A1 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
CN107929731A (zh) | 2005-11-04 | 2018-04-20 | 健泰科生物技术公司 | 利用补体途径抑制剂治疗眼部疾病 |
ES2700609T3 (es) | 2006-11-02 | 2019-02-18 | Genentech Inc | Anticuerpos anti-factor D humanizados y sus usos |
AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US20090317400A1 (en) | 2008-05-05 | 2009-12-24 | Krzysztof Masternak | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
BRPI0912003A2 (pt) | 2008-05-06 | 2016-07-12 | Genentech Inc | afinidade de variantes de crig maturadas |
KR102340685B1 (ko) | 2009-02-20 | 2021-12-17 | 가니메드 파마슈티칼스 게엠베하 | 암의 진단 및 치료를 위한 방법 및 조성물 |
PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
RU2011149798A (ru) | 2009-05-08 | 2013-06-20 | Дженентек, Инк. | Гуманизированные анти-egfl7-антитела и способы их применения |
AT508569A1 (de) | 2009-07-23 | 2011-02-15 | Affiris Ag | Pharmaceutical compound |
BR112012011143B1 (pt) | 2009-11-11 | 2020-05-19 | Ganymed Pharmaceuticals Ag | "anticorpos específicos para claudina 6 (cldn6)". |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
MX341147B (es) | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
AU2012279237B2 (en) | 2011-07-01 | 2016-09-29 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
JP6403685B2 (ja) | 2012-12-27 | 2018-10-17 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法 |
CN110922468A (zh) * | 2013-01-17 | 2020-03-27 | 汉诺威医学院 | 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂 |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
KR20180021234A (ko) | 2013-08-12 | 2018-02-28 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
US9738716B2 (en) | 2014-01-24 | 2017-08-22 | Ngm Biopharmaceuticals, Inc. | Beta klotho binding proteins and methods of use thereof |
WO2015168468A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
GB201906052D0 (en) * | 2019-04-30 | 2019-06-12 | Int Centre For Genetic Engineering And Biotechnology | Proteins with cardioprotective activity |
JP7064179B2 (ja) | 2020-11-30 | 2022-05-10 | 富士電機株式会社 | 水分吸着材 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000690A2 (en) * | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
WO2000053751A1 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
CA2302387A1 (en) * | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | 29 human secreted proteins |
EP1056847A2 (en) * | 1998-02-27 | 2000-12-06 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
DK1490386T3 (da) * | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
WO1999050405A1 (en) * | 1998-03-31 | 1999-10-07 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
JP2003524599A (ja) * | 1998-09-14 | 2003-08-19 | ジェネンテック・インコーポレーテッド | 血管新生と心血管新生の促進又は阻害 |
AU771751C (en) * | 1998-12-01 | 2006-04-06 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
EP1263948A2 (en) * | 1999-03-08 | 2002-12-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
KR100543857B1 (ko) * | 1999-09-01 | 2006-01-23 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
-
2001
- 2001-07-09 JP JP2002514188A patent/JP2004516013A/ja not_active Withdrawn
- 2001-07-09 EP EP01951036A patent/EP1309685A2/en not_active Withdrawn
- 2001-07-09 WO PCT/US2001/021735 patent/WO2002008284A2/en active Search and Examination
- 2001-07-09 AU AU2001271973A patent/AU2001271973A1/en not_active Abandoned
- 2001-07-09 CA CA002416538A patent/CA2416538A1/en not_active Abandoned
-
2008
- 2008-07-29 JP JP2008194678A patent/JP2009039117A/ja not_active Withdrawn
- 2008-07-29 JP JP2008194721A patent/JP2009039118A/ja not_active Withdrawn
- 2008-07-29 JP JP2008194764A patent/JP2009039119A/ja not_active Withdrawn
-
2011
- 2011-08-08 JP JP2011173336A patent/JP6033531B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002008284A2 (en) | 2002-01-31 |
JP2009039117A (ja) | 2009-02-26 |
JP6033531B2 (ja) | 2016-11-30 |
JP2009039118A (ja) | 2009-02-26 |
JP2009039119A (ja) | 2009-02-26 |
WO2002008284A3 (en) | 2003-03-13 |
JP2012005493A (ja) | 2012-01-12 |
EP1309685A2 (en) | 2003-05-14 |
JP2004516013A (ja) | 2004-06-03 |
AU2001271973A1 (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7135334B2 (en) | PRO20044 nucleic acids | |
JP6033531B2 (ja) | 血管形成に関連する障害を診断及び治療するための組成物と方法 | |
US7265210B2 (en) | Anti-PRO9821 antibodies | |
US20040043927A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
CA2412211A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
US20060074033A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US20070191270A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US20060073552A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US20030224984A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
US20060073558A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US7332578B2 (en) | Anti-pro4407 antibodies | |
EP2042597A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
US7238790B2 (en) | PRO1313 polypeptides | |
US20060073556A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
US20060074228A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
EP2075253A1 (en) | Compositions and methds for the diagnosis and treatment of disorders involving angiogensis | |
JP2015037408A (ja) | 血管形成に関連する障害を診断及び治療するための組成物と方法 | |
EP1944317A2 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |